Burning Rock Biotech Limited primarily develops and provides screening tests for cancer therapies in the People's Republic of China. The company is headquartered in Guangzhou, China.
| Revenue (TTM) | $514.43M |
| Gross Profit (TTM) | $383.52M |
| EBITDA | $-44.33M |
| Operating Margin | -17.50% |
| Return on Equity | -10.90% |
| Return on Assets | -4.45% |
| Revenue/Share (TTM) | $48.67 |
| Book Value | $7.51 |
| Price-to-Book | 1.19 |
| Price-to-Sales (TTM) | 0.18 |
| EV/Revenue | 0.425 |
| EV/EBITDA | -0.17 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -18.90% |
| Shares Outstanding | $8.81M |
| Float | $4.06M |
| % Insiders | 4.01% |
| % Institutions | 46.71% |
Volatility is currently expanding